After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months.
Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.
If Biotech manages to break out to new highs at some point this year, it would clear a significant resistance hurdle and open the door up for another big leg higher.
Hinterhaus Productions/DigitalVision via Getty Images
After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months.
Biotech hasn't garnered much attention lately, with all the coverage of